Management View - Acurx Pharmaceuticals, Inc. (ACXP) reported a receipt of $1.4 million in gross proceeds from the execution of Series F Warrants in October 2025 [2] - The company is preparing to launch a pivotal recurrent CDI trial in the second half of 2026 while also strengthening its ibezapolstat pipeline [2]

Financial Data and Key Metrics Changes - The company ended 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [12] - The net loss for Q4 2025 was $1.6 million, or $0.73 per diluted share, compared to a net loss of $2.8 million, or $3.29 per diluted share for Q4 2024 [16] - For the full year 2025, the net loss was $8 million, or $5.32 per diluted share, down from a net loss of $14.1 million, or $17.45 per share in 2024 [16] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to decreased manufacturing and consulting costs [13] - For the full year 2025, R&D expenses totaled $1.8 million, a significant decrease from $5.4 million in 2024, attributed to lower manufacturing and consulting costs [14] - General and administrative expenses for Q4 2025 were $1.3 million, down from $2 million in Q4 2024, mainly due to reduced compensation-related costs and professional fees [14] Market Data and Key Metrics Changes - The company presented at IDWeek in Atlanta, highlighting the potential of ibezapolstat and its microbiome-sparing properties, which could position it favorably in the market [4][5] - The FDA's recent announcement regarding a one-trial requirement for registration could significantly impact the company's clinical development programs and market entry strategy [10] Company Strategy and Development Direction - The company is launching a new clinical trial program for ibezapolstat in patients with recurrent CDI, aiming to shift treatment paradigms from two agents to one [7][19] - The company is pursuing funding opportunities for its phase 3 clinical trial programs and exploring alternative financial pathways [11] - The focus on U.S.-based manufacturing aligns with government interests in public-private partnerships, potentially enhancing funding opportunities [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the macroeconomic challenges and emphasized the competitive profile of ibezapolstat [12] - The potential for ibezapolstat to be the first agent to demonstrate clinical success in both treating and preventing recurrent CDI was highlighted as a significant opportunity [19] - The company is optimistic about the implications of the FDA's new guidance on clinical trial requirements for its development programs [10] Other Important Information - The company received a new patent for its Pol IIIC inhibitors, extending protection to December 2039 [10] - The clinical program for ibezapolstat has received fast track designations from the FDA, enhancing its development prospects [11] Q&A Session Summary Question: What is the primary endpoint for the recurrent CDI trial and its cost? - The primary endpoint is prevention of recurrence, with an evaluation period of eight weeks and a trial cost estimated between $4 million and $5 million [22][32] Question: When will the pilot study start and conclude? - Enrollment for the pilot study is expected to begin in the second half of 2026, with full enrollment anticipated to take 12-15 months [33] Question: How many patients will be needed for the phase 3 trial? - The current projection for the phase 3 trial in recurrent CDI is between 360 and 400 patients, depending on data from the open-label trial [37] Question: Is U.S.-based manufacturing a focus for the company? - Yes, the company is engaging with government agencies regarding U.S.-based manufacturing, which is seen as beneficial for securing funding [41]

Core Insights - Acurx Pharmaceuticals reported significant advancements in its clinical programs and financial results for the year and fourth quarter ended December 31, 2025, highlighting the readiness to advance its antibiotic candidate, ibezapolstat, to Phase 3 trials for treating recurrent C. difficile infections (rCDI) [1][2] Financial Results - The company ended Q4 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [1] - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to reduced manufacturing and consulting costs [1] - General and administrative expenses for Q4 2025 were $1.3 million, a decrease from $2.0 million in Q4 2024, attributed to lower compensation-related costs and professional fees [2] - The net loss for Q4 2025 was $1.6 million or $0.73 per diluted share, compared to a net loss of $2.8 million or $3.29 per diluted share in Q4 2024 [2] Clinical Developments - Acurx's clinical program for the broader CDI patient population is set to advance to Phase 3 international pivotal clinical trials, potentially benefiting from a new FDA standard that may allow for a single pivotal trial for registration [1] - The company is launching a new clinical trial program for ibezapolstat in patients with rCDI, which aims to shift treatment paradigms from two agents to one [1] - Ibezapolstat has shown a 96% clinical cure rate in a Phase 2 trial for acute CDI, with no recurrence while preserving the gut microbiome [1] Intellectual Property and Collaborations - Acurx received a new patent for its Pol IIIC inhibitors, extending protection until December 2039 [1] - The company published significant research results in Nature Communications, demonstrating the binding of ibezapolstat to its target, marking a milestone in its collaboration with Leiden University Medical Center [1] Market Position and Future Outlook - Acurx is well-positioned to commence its international Phase 3 registration program, having received positive regulatory guidance from both the FDA and EMA [2] - The company’s lead product candidate, ibezapolstat, is recognized as a Qualified Infectious Disease Product (QIDP) and has received Fast Track designation from the FDA, highlighting its potential in addressing urgent public health threats [2]

Core Viewpoint - Acurx Pharmaceuticals Inc. shares experienced a significant pullback in premarket trading after a substantial rally, indicating potential overbought conditions in the stock market [1][2]. Clinical Update - Acurx Pharmaceuticals announced a new trial for ibezapolstat targeting patients with recurrent C. difficile infection (rCDI), reporting a 96% clinical cure rate from Phase 2 data [3]. - Enrollment for the new study is set to begin in the fourth quarter [3]. Financial Results - The company is expected to report a loss per share of $1.00 for the fourth quarter of 2025, a decrease from a loss of $3.40 per share a year earlier [4]. Strategic Developments - Acurx is advancing into Phase 3 international studies, contingent on funding, and ibezapolstat has received FDA Fast Track and Qualified Infectious Disease Product designations [5]. Technical Analysis - The stock is trading 162.5% above its 20-day simple moving average (SMA) and 48.3% above its 100-day SMA, indicating a strong short-term performance [6]. - Over the past 12 months, shares have declined by 35.16%, and the stock is currently closer to its 52-week lows of $1.33 than its highs of $21.00 [6]. Price Action - During premarket trading, Acurx Pharmaceuticals shares were down 12.95% at $5.24, with key resistance identified at $5.50 and key support at $5.00 [7].

Group 1 - Acurx Pharmaceuticals Inc shares are experiencing significant gains, with a reported increase of 105.17% to $5.95, attributed to investor reactions to recent developments regarding its antibiotic candidate, ibezapolstat [1][5] - The company is initiating a new clinical trial program for ibezapolstat targeting patients with recurrent C. difficile infection (rCDI) and plans to advance the drug into Phase 3 international studies for the broader CDI population, pending funding [2] - Ibezapolstat has received FDA Fast Track status and is positioned to potentially be the first single agent to treat CDI and prevent recurrent infections, indicating a significant shift in treatment approaches [3] Group 2 - The Relative Strength Index (RSI) for Acurx Pharmaceuticals has surged into the high 80s, indicating that the stock has entered overbought territory following a strong momentum move [4]

Core Insights - Acurx Pharmaceuticals is advancing a new clinical trial program for ibezapolstat in patients with recurrent C. difficile infection (rCDI), which has the potential to change the treatment paradigm from using two agents to one [1][2] - The company has received FDA QIDP and Fast-Track Designation, and is preparing to initiate Phase 3 international clinical trials for ibezapolstat, pending funding [1][2] - Recent Phase 2 trial results showed a 96% clinical cure rate and a 100% sustained clinical cure rate for patients treated with ibezapolstat, indicating its effectiveness in treating CDI and preventing recurrence [1][2][3] Clinical Trial Details - The new open-label trial will enroll up to 20 patients with rCDI who have had at least two recurrences in the past 12 months, with the first patient expected to enroll in Q4 2026 [1] - Acurx plans to conduct an active-controlled Phase 3 registration trial following favorable results from the initial trial, aiming for FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs [1][2] - The Phase 2 clinical trial included a multicenter, open-label segment and a double-blind, randomized segment, demonstrating high efficacy and safety of ibezapolstat [2][3] Efficacy and Safety - In the Phase 2a trial, 100% of patients treated with ibezapolstat were cured at the end of treatment, while the Phase 2b trial showed a 94% clinical cure rate [2][3] - The combined Phase 2 results indicated a 96% clinical cure rate, with 100% of patients remaining free of CDI recurrence for one month after treatment [2][3] - Ibezapolstat was well-tolerated, with no serious drug-related adverse events reported [2] Market Context - C. difficile infection is a significant public health issue, with approximately 500,000 infections and 30,000 deaths annually in the U.S., leading to a healthcare cost burden of around $5 billion [1][3] - The recurrence rate for CDI after treatment with standard antibiotics ranges from 20% to 40%, highlighting the unmet need for effective prevention strategies [3] - Acurx's approach with ibezapolstat aims to address this need by maintaining a healthy gut microbiome while effectively treating CDI [3]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with cash totaling $5.9 million, an increase from $3.7 million as of December 31, 2024 [11] - The net loss for Q3 2025 was $2 million, or $1.23 per diluted share, compared to a net loss of $2.8 million, or $3.45 per diluted share for Q3 2024 [14] - For the nine months ended September 30, 2025, the net loss was $6.4 million, or $5.01 per diluted share, compared to a net loss of $11.3 million, or $14.23 per share for the same period in 2024 [14] Business Line Data and Key Metrics Changes - Research and development expenses for Q3 2025 were $0.4 million, down from $1.2 million in Q3 2024, primarily due to a decrease in manufacturing and consulting costs [11][12] - General and administrative expenses remained consistent at $1.6 million for Q3 2025 compared to Q3 2024, with a slight decrease in compensation-related costs offset by an increase in legal fees [12] Market Data and Key Metrics Changes - The company regained compliance with NASDAQ listing requirements after a 1-for-20 reverse stock split on August 4, 2025 [4][5] - Acurx has obtained multiple patents for its DNA polymerase 3C inhibitors, including a new patent granted by the Australian Patent Office [5][8] Company Strategy and Development Direction - The company is focused on advancing its ibezapolstat program, which has shown promising results in treating C. diff infections [9][10] - Acurx is pursuing funding opportunities for a phase three clinical trial program for ibezapolstat and is considering alternative pathways for success [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the macroeconomic environment and industry challenges while continuing to strengthen ibezapolstat's competitive profile [10] - The company recognizes November as C. diff Awareness Month and supports initiatives for education and prevention [10] Other Important Information - The company has FDA QIDP and FAST TRACK designations for ibezapolstat, which could significantly impact the economic burden of C. diff infections in the U.S. [10] - Acurx is actively engaged in scientific collaborations, with recent publications highlighting the structural biology of ibezapolstat [8] Q&A Session Summary Question: Potential for FDA to prioritize domestically manufactured novel antibiotics - Management sees potential for increased prioritization but noted uncertainty regarding the PASTOR Act and its impact on antibiotic funding [18][19] Question: Impact of proposed clinical priority review voucher framework - The regulatory approach and commercial strategy will remain the same, with plans to utilize the program at the appropriate time [21][22] Question: Filing for approval based on phase two ibezapolstat data - Management indicated that a safety database is required, and phase three trial data will be necessary for regulatory approval [23][25] Question: Timing around potential partnership discussions - Management expressed optimism about potential partnership news by the next earnings call but could not provide specific timelines [36][37] Question: QIDP and FAST TRACK designation expectations - Once obtained, these designations are maintained indefinitely without specific movement requirements [38] Question: Future operational expenses - Management anticipates that operational costs will continue to gradually decrease while maintaining a steady financial position [39]

Core Insights - Acurx Pharmaceuticals reported financial and operational results for Q3 2025, highlighting a cash position of $5.9 million, an increase from $3.7 million at the end of 2024, and a net loss of $2.0 million for the quarter, an improvement from a net loss of $2.8 million in Q3 2024 [2][6]. Financial Performance - Cash Position: The company ended Q3 2025 with $5.9 million in cash, up from $3.7 million at the end of 2024. The company raised approximately $1.7 million through an Equity Line of Credit and an additional $1.4 million from a warrant exercise post-quarter [2]. - R&D Expenses: R&D expenses for Q3 2025 were $0.4 million, down from $1.2 million in Q3 2024, primarily due to reduced manufacturing and consulting costs. For the nine months ended September 30, 2025, R&D expenses totaled $1.6 million compared to $4.6 million in the same period of 2024 [3]. - G&A Expenses: General and administrative expenses remained stable at $1.6 million for Q3 2025, consistent with Q3 2024. For the nine months ended September 30, 2025, G&A expenses were $4.9 million, down from $6.8 million in 2024 [4][5]. - Net Income/Loss: The company reported a net loss of $2.0 million or $1.23 per diluted share for Q3 2025, compared to a net loss of $2.8 million or $3.45 per diluted share in Q3 2024. For the nine months ended September 30, 2025, the net loss was $6.4 million, improving from $11.3 million in the same period of 2024 [6]. Operational Highlights - Patent Developments: In September 2025, Acurx received a new patent from the Australian Patent Office for its class of DNA polymerase IIIC inhibitors, adding to its existing patents in the U.S., Israel, Japan, and India [4]. - Stockholder Approval: Stockholders approved an amendment to increase the total number of authorized shares from 200 million to 250 million, which was filed with the Delaware Secretary of State [4]. - Conference Presentation: In October 2025, Acurx presented at IDWeek in Atlanta, discussing the microbiome-sparing properties of its lead antibiotic candidate, ibezapolstat [4]. - Scientific Publication: Acurx announced the publication of research in Nature Communications, detailing the structural biology of ibezapolstat, marking a significant milestone in its collaboration with Leiden University Medical Center [4]. Product Development - Ibezapolstat: The lead antibiotic candidate is preparing for international Phase 3 clinical trials to treat C. difficile Infection (CDI). It is a novel, orally administered antibiotic with a Gram-Positive Selective Spectrum [8][10]. - Regulatory Guidance: Acurx received positive regulatory guidance from the EMA, confirming that its clinical and non-clinical data supports the advancement of the ibezapolstat Phase 3 program [9].

As filed with the Securities and Exchange Commission on October 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACURX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form ...

Core Insights - Several companies have experienced significant stock price increases, attracting investor attention and market analysis [1] Company Summaries - **Xenetic Biosciences, Inc.**: Achieved a 142.31% increase in stock price, closing at $10.39, with a trading volume of 45,373,947. The company focuses on immuno-oncology technologies and has expanded its partnership with The Scripps Research Institute to advance CAR T-cell therapies [2] - **bioAffinity Technologies, Inc.**: Stock price rose by 108.60% to $0.48, with a volume of 29,850. The company specializes in non-invasive cancer diagnosis and treatment, showcasing the clinical value of its CyPath® Lung in detecting early-stage lung cancer [3] - **GigCapital7 Corp.**: Recorded an 89.43% increase in stock price, ending at $1.58. This SPAC is gaining interest due to its business combination with BigBear.ai, which has a pro forma enterprise value of $1.378 billion and aims to capitalize on AI/ML market opportunities [4] - **AlphaTON Capital Corp.**: Experienced an 85.48% rise in stock price to $10.35. The company is transitioning to a digital asset treasury model focused on Toncoin (TON) and is exploring the tokenization of single-indication economics for mesothelioma [5] - **Acurx Pharmaceuticals, Inc.**: Stock price increased by 74.36% to $7.48. The company is developing antibiotics for bacterial infections and received a positive opinion from the European Medicines Agency for its Pediatric Investigation Plan, positioning it for international Phase 3 clinical trials [6] Market Dynamics - The performances of these companies illustrate the dynamic nature of the stock market and the potential for significant returns, prompting investors and analysts to monitor future developments closely [7][8]